CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 165 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2015. The put-call ratio across all filers is 4.61 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $16,241,000 | -0.4% | 4,587,716 | +13.7% | 0.00% | 0.0% |
Q3 2016 | $16,302,000 | -1.4% | 4,035,089 | +7.1% | 0.00% | -25.0% |
Q2 2016 | $16,539,000 | +21.5% | 3,767,356 | +4.6% | 0.00% | +33.3% |
Q1 2016 | $13,609,000 | -75.8% | 3,600,323 | +0.4% | 0.00% | -76.9% |
Q4 2015 | $56,221,000 | +41.8% | 3,585,519 | -4.7% | 0.01% | +30.0% |
Q3 2015 | $39,651,000 | -56.8% | 3,761,916 | +3.4% | 0.01% | -54.5% |
Q2 2015 | $91,796,000 | -11.4% | 3,639,813 | -2.1% | 0.02% | -12.0% |
Q1 2015 | $103,645,000 | +69.9% | 3,718,889 | +11.3% | 0.02% | +66.7% |
Q4 2014 | $60,986,000 | +55.1% | 3,341,726 | +10.1% | 0.02% | +36.4% |
Q3 2014 | $39,324,000 | -21.2% | 3,034,230 | -0.8% | 0.01% | -21.4% |
Q2 2014 | $49,902,000 | -15.7% | 3,057,751 | -8.7% | 0.01% | -22.2% |
Q1 2014 | $59,195,000 | -22.4% | 3,350,054 | +6.4% | 0.02% | -21.7% |
Q4 2013 | $76,235,000 | -27.9% | 3,148,910 | +5.5% | 0.02% | -36.1% |
Q3 2013 | $105,790,000 | +160.5% | 2,985,877 | +14.8% | 0.04% | +140.0% |
Q2 2013 | $40,616,000 | – | 2,601,925 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
Bellevue Group AG | 160,000 | $646,000 | 0.12% |
PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |